Press Release: Incyte to Report First Quarter Financial Results

Dow Jones04-09
WILMINGTON, Del.--(BUSINESS WIRE)--April 09, 2026--

Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 28, 2026.

The schedule for the press release and conference call/webcast is as follows: 

   --  Q1 2026 Press Release: April 28, 2026 at 7:00 a.m. ET 
 
   --  Q1 2026 Conference Call: April 28, 2026 at 8:00 a.m. ET 
 
   --  Domestic Dial-In Number: 877-407-3042 
 
   --  International Dial-In Number: 201-389-0864 
 
   --  Conference ID Number: 13759527

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13759527.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte$(R)$

Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409506560/en/ 

 
    CONTACT:    Incyte Contacts

Media

media@incyte.com

Investors

ir@incyte.com

(END) Dow Jones Newswires

April 09, 2026 08:02 ET (12:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment